Evogliptin Tartrate
- CAS号:1222102-51-3
- 英文名:Evogliptin Tartrate
- 中文名:Evogliptin Tartrate
- CBNumber:CB15984681
- 分子式:C19H26F3N3O3 · (C4H6O6)
- 分子量:551.52
- MOL File:1222102-51-3.mol
- 储存条件 :Store at -20°C
- 溶解度 :DMSO: 100 mg/mL (181.32 mM)
- 形态 :Solid
- 颜色 :White to off-white
Evogliptin Tartrate性质、用途与生产工艺
- 生物活性 Evogliptin tartrate 是一种高效、口服有效、选择性的 DPP-4 抑制剂，具有抗糖尿病活性。Evogliptin tartrate 可用于靶向动脉炎症和动脉粥样硬化的研究。
-
靶点
DPP-4
-
体外研究
Evogliptin tartrate significantly inhibits the TNF-α-mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC 50 = 0.30 and 0.25 μM, respectively).
Evogliptin tartrate inhibits the TNF-α-mediated transcriptional activation of ICAM-1 and VCAM-1.
Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF-α. And TNF-α-mediated activation of NF-κB is ameliorated by evogliptin via the interaction of NF-κB with SIRT1.
Cell Viability Assay
Cell Line: Endothelial cells Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM Incubation Time: 12 hours Result: Inhibits TNF-α-mediated (10 ng/ml) expression of adhesion molecules. -
体内研究
Evogliptin tartrate (37.5-150 mg/kg; p.o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE −/− mouse model.
Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability.
Animal Model: ApoE −/− mice Dosage: 37.5 mg/kg, 75 mg/kg, 150 mg/kg Administration: Oral administration; daily; for 12 weeks Result: Inhibit the development of atherosclerosis.
- 更新日期：2024/11/08
- 产品编号：HY-117985B
- 产品名称：Evogliptin tartrate
- CAS编号：
- 包装：1 mg
- 价格：1590元
- 更新日期：2024/11/08
- 产品编号：HY-117985B
- 产品名称：Evogliptin Tartrate Evogliptin tartrate
- CAS编号：1222102-51-3
- 包装：5mg
- 价格：3500元
- 公司名称：Toronto Research Chemicals Inc.
- 联系电话：--
- 电子邮件：info@trc-canada.com
- 国家：加拿大
- 产品数：6668
- 优势度：58
